Clinical Trial

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Study acronym: TASK-05
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-02; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-10
Trial Details
NCT Number NCT07105748
Lead Sponsor Fudan University
Conditions Mixed Hepatocellular-cholangiocarcinoma
Enrollment 45 participants
Start Date 2025-08-15
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17